Clinical Trial Detail

NCT ID NCT01727336
Title Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acceleron Pharma, Inc.
Indications

renal cell carcinoma

Therapies

Axitinib + Dalantercept

Axitinib

Age Groups: adult

No variant requirements are available.